Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash from Operations (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Cash from Operations data on record, last reported at 14176000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations fell 173.22% year-over-year to 14176000.0; the TTM value through Dec 2025 reached 45327000.0, up 151.59%, while the annual FY2025 figure was 45327000.0, 151.59% up from the prior year.
  • Cash from Operations reached 14176000.0 in Q4 2025 per APLS's latest filing, down from 108468000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 108468000.0 in Q3 2025 and bottomed at 177620000.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 85707250.0, with a median of 112029500.0 recorded in 2021.
  • Peak YoY movement for Cash from Operations: plummeted 179.24% in 2021, then skyrocketed 218.13% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 112499000.0 in 2021, then decreased by 25.11% to 140744000.0 in 2022, then skyrocketed by 30.46% to 97875000.0 in 2023, then surged by 119.78% to 19360000.0 in 2024, then crashed by 173.22% to 14176000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 14176000.0 in Q4 2025, 108468000.0 in Q3 2025, and 4445000.0 in Q2 2025.